Last update 14 Dec 2024
Anti-CD30 CAR T-cell therapy(Bio-Raid)
Last update 14 Dec 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms 靶向CD30嵌合抗原受体基因修饰的自体T细胞（武汉波睿达生物）, BRD 01, BRD-01 + [1] |
Target |
Mechanism CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Login to view timeline
Related
3
Clinical Trials associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)评估靶向 CD30 嵌合抗原受体基因修饰的自体 T 细胞注射液在 CD30 阳性复发/难治性经典型霍奇金淋巴瘤患者中有效性及安全性的 Ⅱ 期临床研究
[Translation] Phase II clinical study to evaluate the efficacy and safety of autologous T cell injection modified with chimeric antigen receptor targeting CD30 in patients with CD30-positive relapsed/refractory classical Hodgkin's lymphoma
靶向CD30嵌合抗原受体基因修饰的自体T细胞注射液在CD30+复发/难治性血液肿瘤患者中安全性及初步疗效的开放标签的Ⅰ期临床研究
[Translation] An open-label phase I clinical study on the safety and preliminary efficacy of autologous T cell injection modified with chimeric antigen receptor targeting CD30 in patients with CD30+ relapsed/refractory hematological malignancies
Efficacy and Safety of Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies：a Single-center, Open, Single-arm Clinical Study.
100 Clinical Results associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
Login to view more data
100 Translational Medicine associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
Login to view more data
100 Patents (Medical) associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
Login to view more data
100 Deals associated with Anti-CD30 CAR T-cell therapy(Bio-Raid)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD30+ Hodgkin's Lymphoma | Phase 2 | CN | 14 May 2024 | |
| Adult T-Cell Leukemia-Lymphoma | Phase 1 | CN | 03 Jul 2019 | |
| Anaplastic Large-Cell Lymphoma | Phase 1 | CN | 03 Jul 2019 | |
| Extranodal NK-T-Cell Lymphoma | Phase 1 | CN | 03 Jul 2019 | |
| Immunoblastic Lymphadenopathy | Phase 1 | CN | 03 Jul 2019 | |
| Peripheral T-Cell Lymphoma | Phase 1 | CN | 03 Jul 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free